Monitoring Visits Workflow | GMPify Training

📋

Monitoring Visits - The Sponsor's Window Into Site Conduct

Monitoring is the process by which a sponsor confirms that a trial is being conducted, recorded, and reported in accordance with the protocol, GCP, and applicable regulation, and that subject rights and safety are being protected. ICH E6(R2) requires a monitoring approach appropriate to the specific risks of the trial, ranging from on-site visits to centralized, risk-based methods. This map details the pathway from monitoring plan development through pre-study, initiation, routine, and closeout visits, and the follow-up cycle that closes each finding.

ICH E6(R2) Section 5.18 · 21 CFR 312.50 · FDA Risk-Based Monitoring Guidance 2013

ICH E6(R2)

21 CFR 312.50

FDA RBM 2013

Pre-Study Visit

Assesses a candidate site's capability, facilities, and patient population before selection, ahead of any trial activity.

Timing: Before site selection

Site Initiation Visit

Confirms the site is ready to enroll, with trained staff, regulatory documents in place, and supplies on hand.

Timing: Before first enrollment

Routine Monitoring Visit

Ongoing visits verifying source data, protocol adherence, and safety reporting throughout active enrollment and follow-up.

Timing: Per monitoring plan cadence

Closeout Visit

Confirms all queries resolved, product reconciled, and essential documents complete once the site's participation ends.

Timing: End of site participation

Phase 1

Monitoring Plan Development

1Develop the risk-based monitoring plan

Monitoring approach defined based on trial risk, investigational product complexity, and site experience, per ICH E6(R2) and FDA RBM guidance.

ICH E6(R2) Section 5.18.3

↓

2Define monitoring visit frequency and triggers

Visit cadence set by enrollment rate, protocol complexity, and site performance, with triggers defined for unscheduled visits when risk indicators arise.

FDA RBM Guidance 2013

↓

3Establish source data verification sampling strategy

SDV approach defined, whether full verification or a targeted, risk-based sample focused on critical data points and safety information.

FDA RBM Guidance 2013

↓

4Train monitors on protocol and monitoring plan

Monitors trained on the specific protocol, investigational product handling, and the monitoring plan's visit and reporting requirements before the first visit.

ICH E6(R2) Section 5.18.1

Phase 2

Visit Preparation and Site Visits

5Conduct pre-study site visit

Candidate site evaluated for facilities, staff experience, patient population access, and capability to conduct the trial per protocol.

ICH E6(R2) Section 5.18

↓

6Conduct site initiation visit

Site staff trained on the protocol and procedures, regulatory documents confirmed complete, and supplies verified before enrollment opens.

ICH E6(R2) Section 5.18

↓

7Prepare visit report and confirmation letter

Written monitoring visit report completed after each visit, summarizing findings and actions, with a confirmation letter sent to the site.

ICH E6(R2) Section 5.18.6

↓

Does the visit identify a finding requiring corrective action?

YES → Issue corrective action request NO → Confirm site on track

Phase 3

Routine Monitoring Visit Conduct

8Verify source data against case report forms

Case report form entries checked against source documents per the sampling strategy, confirming accuracy, completeness, and traceability.

ICH E6(R2) Section 5.18.4

↓

9Confirm protocol and GCP compliance

Site practices reviewed against the protocol and GCP, including informed consent process, eligibility criteria application, and safety reporting timeliness.

ICH E6(R2) Section 5.18.4

↓

10Reconcile investigational product accountability

Investigational product receipt, dispensing, storage conditions, and return records reconciled against the accountability log.

21 CFR 312.50

Phase 4

Findings Follow-Up and Closeout

11Track corrective actions to closure

Findings tracked from identification through documented resolution, with verification at the subsequent visit before closure.

ICH E6(R2) Section 5.18.6

↓

12Escalate unresolved findings

Findings not resolved within the expected timeframe escalated per the sponsor's defined escalation pathway, up to and including site risk reassessment.

ICH E6(R2) Section 5.18

↓

13Conduct closeout visit and final reconciliation

Final visit confirms all queries resolved, investigational product reconciled, and essential documents complete before the site's participation ends.

ICH E6(R2) Section 5.18

Monitoring Visit Types and Purpose

Pre-Study and Initiation Visits

Confirm site capability before selection and readiness before enrollment. Focused on infrastructure, staff training, and document completeness.

ICH E6(R2) Section 5.18

Routine Monitoring Visits

Ongoing verification of source data, protocol adherence, and product accountability, at a frequency set by the risk-based monitoring plan.

ICH E6(R2) Section 5.18.3

Closeout Visits

Final confirmation that all outstanding items are resolved and the site's records are complete before its participation formally ends.

ICH E6(R2) Section 5.18

Source Data Verification Approach (Overview)

100% SDV Every data point verified against source documents. Resource-intensive, typically reserved for high-risk trials or critical endpoints.

Targeted / risk-based SDV Verification focused on critical data points, such as eligibility, primary endpoints, and safety data, with reduced verification elsewhere.

Centralized and remote monitoring Statistical review of aggregated data across sites to identify outliers and trends, supplementing or partially replacing on-site visits.

Sampling strategy documentation The chosen approach and its rationale documented in the monitoring plan, so the level of verification applied is traceable and justified.

Common Monitoring Finding Categories (Overview)

Source documentation gaps Case report form entries without a supporting source document, or source records that are incomplete or not contemporaneous.

Protocol deviations Departures from the approved protocol identified during source review, ranging from visit window issues to eligibility questions.

Product accountability discrepancies Dispensing or return records that do not reconcile with the investigational product accountability log.

Regulatory document currency Expired approvals, outdated delegation logs, or missing training records identified in the site's regulatory binder.

Monitoring Visit Quality Elements

Risk-Based Monitoring Plan Documented plan defining monitoring approach, visit frequency, and SDV sampling strategy scaled to trial and site risk.

Visit Frequency Justification Rationale for the chosen visit cadence, tied to enrollment rate, protocol complexity, and observed site performance.

Source Data Verification Case report form data checked against source documents per the defined sampling strategy at every routine visit.

Regulatory Binder Review Site regulatory documents, including approvals, delegation logs, and training records, confirmed current at each visit.

Investigational Product Accountability Dispensing, storage, and return records reconciled against the accountability log at every applicable visit.

Informed Consent Verification Consent documentation confirmed complete and properly dated relative to study procedures for every enrolled subject.

Corrective Action Tracking Findings tracked from identification through documented, verified resolution rather than closed on the site's word alone.

Visit Report Documentation Written report and site confirmation letter completed for every visit, forming part of the trial master file record.

Never do this

Skip a scheduled monitoring visit without documented justification and a revised plan. Close a finding without verifying the corrective action at the next visit. Apply a fixed SDV percentage without a documented risk-based rationale. Leave a site's regulatory binder unreviewed for multiple consecutive visits.

On-site vs centralized monitoring

On-site monitoring involves a monitor physically reviewing records at the site. Centralized monitoring uses statistical analysis of data across sites to identify risk signals remotely. Most modern monitoring plans blend both approaches based on trial risk.

Monitoring vs auditing

Monitoring is an ongoing sponsor function verifying day-to-day trial conduct at the site level. Auditing is an independent, periodic sponsor quality function assessing whether monitoring and site processes themselves are working as intended.

Key regulations

ICH E6(R2) Section 5.18 - monitoring requirements and risk-based approach. 21 CFR 312.50 - sponsor monitoring responsibilities. FDA Risk-Based Monitoring Guidance 2013 - risk-based monitoring methodology and rationale.